Literature DB >> 10858054

Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.

I F Comaish, C Gorman, N R Galloway.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858054      PMCID: PMC1118060     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  8 in total

1.  Visual field defect associated with vigabatrin: observational cohort study.

Authors:  L V Wilton; M D Stephens; R D Mann
Journal:  BMJ       Date:  1999-10-30

2.  Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings.

Authors:  N R Miller; M A Johnson; S R Paul; C A Girkin; J D Perry; M Endres; G L Krauss
Journal:  Neurology       Date:  1999-12-10       Impact factor: 9.910

3.  Study is needed of visual field defects associated with any long term antiepileptic drug.

Authors:  G P Rao; F A Fat; G Kyle; J P Leach; D W Chadwick; M Batterbury
Journal:  BMJ       Date:  1998-07-18

4.  Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.

Authors:  I C Wong; G E Mawer; J W Sander
Journal:  BMJ       Date:  1997-06-07

5.  Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.

Authors:  N Blackwell; J Hayllar; G Kelly
Journal:  BMJ       Date:  1997-06-07

6.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

7.  Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects.

Authors:  R Kälviäinen; I Nousiainen; M Mäntyjärvi; E Nikoskelainen; J Partanen; K Partanen; P Riekkinen
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

8.  Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

Authors:  G L Krauss; M A Johnson; N R Miller
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.